Organization (Industry)
Aadi Bioscience, Inc.
ClinicalTrials.gov lists Aadi Bioscience, Inc. as lead sponsor of 11 trials. It has 18 active development programs and 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Aadi Bioscience, Inc.: 11 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (34)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Endometrial Neoplasms | 3 |
| Ovarian Neoplasms | 3 |
| Perivascular Epithelioid Cell Neoplasms | 3 |
| Sarcoma | 3 |
| Carcinoma, Non-Small-Cell Lung | 2 |
Showing 5 of 34 disease areas.
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 3 |
| 2022 | 3 |
| 2019 | 2 |
| 2018 | 4 |
| 2017 | 2 |
| 2015 | 1 |
| 2014 | 1 |
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (18)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Nab-Sirolimus | Endometrial Neoplasms | Phase 2 | 1 |
| Nab-Sirolimus | Recurrence | Phase 2 | 1 |
| Nab-Sirolimus | Adenoma, Islet Cell | Phase 2 | 1 |
| Nab-Sirolimus | Hereditary Sensory and Autonomic Neuropathies | Phase 2 | 1 |
| Nab-Sirolimus | Neoplasm Metastasis | Phase 2 | 1 |
Showing 5 of 18 active programs.
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| GEMCITABINE | 1 |
| BEVACIZUMAB | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 50% hit target (n=8) | 29% on time (n=7) |
Journals published in (4)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2 |
| Clinical cancer research : an official journal of the American Association for Cancer Research | 1 |
| Expert opinion on emerging drugs | 1 |
| Future oncology (London, England) | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 8 | 0 | 2021-10-05 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 7,145,000 | -20,596,000 | 90,963,000 |
| 2024 | 25,983,000 | -63,691,000 | 51,030,000 |
| 2023 | 24,354,000 | -65,765,000 | 48,929,000 |
| 2022 | 15,216,000 | -60,513,000 | 32,662,000 |
| 2021 | 14,000,000 | -110,090,000 | 19,670,000 |
| 2020 | 14,000,000 | -3,478,000 | 15,008,000 |
| 2019 | 0 | -23,270,514 | 12,824,402 |
| 2018 | 20,157,430 | -10,396,635 | 17,852,756 |
| 2017 | not reported | -21,400,606 | 12,147,132 |
| 2016 | not reported | -16,983,511 | 11,367,590 |
Showing 10 of 11 fiscal years.
Financing and grant events (35)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-05-21 | Royalty / licensing | not disclosed | Sec extracted |
| 2026-05-12 | Private placement | not disclosed | Sec extracted |
| 2025-04-25 | Other financing | not disclosed | Edgar offerings |
| 2025-03-31 | Other financing | not disclosed | Edgar offerings |
| 2025-03-25 | Other financing | 102,400,000 | Sec extracted |
Showing 5 of 35 events.
FDA untitled letters (1)
| Issue date | Letter |
|---|---|
| 2025-09-09 | 188963 |
FDA recalls (1)
| Product | Classification | Initiated |
|---|---|---|
| Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound), 100 mg per vial, NDC 80803-153-50, manufactured for Aadi Bioscience, Inc, CA. | Class III | 2022-10-13 |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (6)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University of Oklahoma | Co sponsors trial with | 1 |
| Mass General Brigham | Co sponsors trial with | 1 |
| Catalyst Pharmaceutical Research | Co sponsors trial with | 1 |
| Sarcoma Oncology Research Center, LLC | Co sponsors trial with | 1 |
| M.D. Anderson Cancer Center | Co sponsors trial with | 1 |
Showing 5 of 6 relationships.
Latest dated events (65)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-05-21 | Royalty / licensing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-05-12 | Private placement | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-03-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-19 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-09 | FDA untitled letter | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
Showing 5 of 65 events.
Biomarker capability evidence (91)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CYP3A4 | Trial collaborator | Named in trial inclusion criteria |
| EGFR | Trial sponsor | Named in trial inclusion criteria |
| KRAS | Trial collaborator | Named in trial inclusion criteria |
| PAPOLA | Trial sponsor | Named in trial inclusion criteria |
| PDCD1 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 91 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, fda warning letters, fda inspection record, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.